As expected, tumors responding to short-term abemaciclib therapy showed reductions in tumor cell proliferation (reduced Ki67 and E2F target gene expression) and consistent with our in vitro data, resistant tumors showed restoration of these parameters to an intermediate level between that of untreated and responding tumors (Supplementary Fig. S10C and S10D). Here, MKI67 is linked to neoplasm.